Roche vs Pfizer vs Amgen and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Roche 17.5245, Pfizer 14.451, Amgen 8.618, AstraZeneca 15.288.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Roche, Pfizer, Amgen, AstraZeneca.| Metric | Roche | Pfizer | Amgen | AstraZeneca |
|---|---|---|---|---|
| Market Cap | $348.66B | $140.64B | $202.95B | $264.21B |
| Revenue | $35.05B | $14.45B | $8.62B | $15.29B |
| Cost of Revenue | $9.21B | $4.73B | $2.74B | $2.68B |
| Gross Profit | $25.84B | $9.72B | $5.87B | $12.61B |
| Operating Income | $10.90B | $4.03B | $2.67B | $4.25B |
| Net Income | $7.93B | $2.69B | $1.82B | $3.08B |
| R&D Expense | $8.35B | $2.63B | $1.72B | $3.49B |
| Earnings Per Share | $1.23 | $0.47 | $3.34 | $3.94 |
| Gross Margin | 73.7% | 67.3% | 68.2% | 82.5% |
| Operating Margin | 31.1% | 27.9% | 30.9% | 27.8% |
| Net Profit Margin | 22.6% | 18.6% | 21.1% | 20.1% |
| Free Cash Flow | $6.46B | $2.18B | $1.48B | $1.82B |
| Cumulative Free Cash Flow | $305.80B | $356.40B | $165.69B | $119.09B |
| Operating Cash Flow | $8.28B | $2.62B | $2.19B | $3.36B |
| Cash & Equivalents | $6.13B | $1.70B | $12.04B | $7.56B |